News

Contract Pharma1d
Thermo Fisher Streamlines Pre-Clinical Biologic Drug Development
Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines ...
Contract Pharma8d
Overcoming Challenges in Early Phase Drug Product Development
Scale-up is a common problem encountered in all forms of development across industries, and oral solid dose manufacturing ...
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical ...
Palatin Announces Breakthrough Symptom Resolution In Updated Analyses From Phase 3 PL9643 MELODY-1 Clinical Trial In Dry Eye Disease
Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye disease. <li ...
Taiwan News9h
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous ...
Biomednewsbreaks - Nanoviricides (NYSE American: NNVC) Advances Measles Drug Development With Broad-Spectrum Antiviral NV-387
NanoViricides, Inc. (NYSE American: NNVC) provided an update on its Measles drug development program, highlighting the potential of its broad-spectru ...
Taiwan News1d
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure – – Combination of ziftomenib and imatinib shows robust and ...
Morningstar6d
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody ... 1310 data at ASCO and outline the next steps in clinical development. Date/Time: Monday, June 2, 2025, at 7:00 a.m. CT ...